Month: March 2026

California Resources Corporation Reports Fourth Quarter and Full-Year 2025 Financial and Operating Results; Announces 2026 Guidance

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

25% Year-Over-Year Production Growth and Highest Annual Free Cash Flow Since 2021 Receipt of New Drilling Permits Supports Planned 2026 Drilling Program LONG BEACH, Calif., March 02, 2026 (GLOBE NEWSWIRE) — California Resources Corporation (NYSE: CRC) (CRC) today reported its financial and operating results for the fourth quarter and full-year 2025. The Company plans to host a conference call and webcast at 1 p.m. ET (10 a.m. PT) on Monday, March 2, 2026. Conference call details can be found within this release. Fourth Quarter HighlightsReported net income of $12 million, adjusted net income1 of $40 million and $251 million of adjusted EBITDAX1 Generated net cash provided by operating activities of $235 million and $115 million of free cash flow1 Delivered an average of 137 thousand barrels of oil equivalent per day5 (MBoe/d)...

Yukon Metals Appoints Jim Coates as Permanent Full-Time CEO

Written by Customer Service on March 2, 2026. Posted in Public Companies.

VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company) is pleased to announce that Jim Coates, who has been serving as Interim CEO, has been appointed as the Company’s permanent full-time Chief Executive Officer, effective immediately. In his role, Mr. Coates will continue to lead the execution of Yukon Metals’ strategic exploration priorities, including executing drill programs at each of the Birch and AZ projects beginning in Q2, building upon the objectives advanced during his interim tenure. Jim Coates, CEO & Director stated: “I have worked closely with our team over the last two years, first as a Director, then Executive Vice President and more recently as Interim CEO, and have gained an understanding of the immense potential...

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030 $200 million funded at closing to refinance the existing $125 million debt facility and provide additional non-dilutive capital Additional $50 million tranche available at Company’s discretion until June 30, 2027 PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, announced it has entered into an agreement with funds managed by Pharmakon Advisors, LP (Pharmakon) to revise the terms of its loan agreement entered into in March 2024. On February 26, 2026, the Company entered into an amended and restated loan agreement with funds managed by Pharmakon...

Xanadu and Crane Harbor Announce SEC Declaration of Effectiveness of Form F-4 Registration Statement

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

TORONTO, March 02, 2026 (GLOBE NEWSWIRE) — Xanadu Quantum Technologies Inc. (“Xanadu”), a global leader in photonic quantum computing, and Crane Harbor Acquisition Corp. (Nasdaq: CHAC) (“Crane Harbor”), a publicly traded special purpose acquisition company, today announced that the U.S. Securities and Exchange Commission (the “SEC”) has declared effective the companies’ joint registration statement on Form F-4 in connection with their previously announced proposed business combination. This marks a significant milestone in the transaction process and moves Xanadu substantially closer to becoming a publicly traded company. The business combination is expected to close in the first quarter of 2026, subject to the satisfaction of customary closing conditions, including the approval by Crane Harbor and Xanadu shareholders and the listing...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

– Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 – – Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA – – Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 trial design to be presented at MDA – – Advancing four development candidates for the potential treatment of DMD amenable to skipping of exons 53, 45, 44, and 55 – – Year-end cash of $1.1 billion; reaffirming expected cash runway into Q1 2028 – WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) — Dyne...

TEGNA Inc. Reports Fourth Quarter and Full-Year 2025 Results

Written by Customer Service on March 2, 2026. Posted in Earnings Releases And Operating Results.

Achieves or exceeds all previously announced full-year 2025 guidance metrics On track to complete proposed acquisition by Nexstar Media Group by the second half of 2026, subject to regulatory approvals and customary closing conditions MCLEAN, Va., March 02, 2026 (GLOBE NEWSWIRE) — TEGNA Inc. (NYSE: TGNA) today announced financial results for the fourth quarter and full-year 2025, ended December 31, 2025. FOURTH QUARTER FINANCIAL HIGHLIGHTS:All Year-Over-Year Comparisons Unless Otherwise Noted:Total company revenue was down 19% from the prior year at $706 million primarily due to lower political advertising revenue, consistent with cyclical even-to-odd year comparisons partially offset by growth in Advertising and Marketing Services (AMS) revenue. Distribution revenue was slightly lower at $358 million due to subscriber declines,...

Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.085 per Share for March 2026

Written by Customer Service on March 2, 2026. Posted in Dividend Reports And Estimates.

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) — Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) announced today a monthly distribution of $0.085 per share for March 2026. This distribution is payable to common stockholders on March 31, 2026 (as outlined in the table below). The Company declares and pays distributions monthly. Payment of future distributions is subject to the approval of the Company’s Board of Directors, as well as meeting the covenants on the Company’s debt agreements and the terms of its preferred stock.Record Date / Ex-Date Payment Date Distribution Amount Return of Capital Estimate3/13/26 3/31/26 $0.085 50%(1)(1) This estimate is based on the Company’s anticipated earnings and profits. The final determination of the tax character of distributions will not be determinable until after the...

Nexxen Announces February 2026 Share Repurchase Program Summary

Written by Customer Service on March 2, 2026. Posted in Public Companies.

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) — Nexxen International Ltd. (NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, flexible advertising technology platform with deep expertise in data and advanced TV, today announced that it repurchased 496,981 shares at an average price of $6.02 during February 2026. As of February 28, 2026, Nexxen had 55,720,779 Ordinary Shares outstanding (excluding treasury shares), and approximately $2.0 million remaining under its current share repurchase authorization. As previously disclosed, the Company has received authorization to initiate a new share repurchase program (the “new program”) of up to $40 million, which is scheduled to begin upon completion of its current program. Under the new program, Nexxen will not be obligated to repurchase any specific number of shares, and the program may...

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Written by Customer Service on March 2, 2026. Posted in Mergers And Acquisitions.

HEMANGEOL® is the only FDA-approved treatment for infantile hemangioma HEMANGEOL will be commercialized by Eton beginning May 1st HEMANGEOL will be distributed through the company’s Eton Cares™ patient support program, which includes a $0 co-pay initiative, to broaden patient access.DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy. “As the only treatment for infantile hemangiomas that...

Statkraft AS: Release of fourth quarter results 2025 and annual report for 2025

Written by Customer Service on March 2, 2026. Posted in Public Companies.

Statkraft discloses fourth quarter results 2025 and the annual report for 2025 on Thursday 5 March 2026 at 08:00 a.m. CET. Material will be available on Statkraft’s website https://www.statkraft.com/IR/ and Oslo Stock Exchange’s news service www.newsweb.no. Webcast09:30 a.m. CET: Statkraft presents the results in a webcast at www.statkraft.com. The presentation will be held in English. Contact:Arild Ratikainen, Investor Contact, tlf.: +47 971 74 132, e-mail: arild.ratikainen@statkraft.com

Month: March 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals